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Individuals who are homozygous for the 32-bp deletion in the gene coding for the chemokine receptor and
major human immunodeficiency virus type 1 (HIV-1) coreceptor CCR5 (CCR5 2/2) lack functional cell
surface CCR5 molecules and are relatively resistant to HIV-1 infection. HIV-1 infection in CCR5 2/2 indi-
viduals, although rare, has been increasingly documented. We now report that the viral quasispecies from one
such individual throughout disease is homogenous, T cell line tropic, and phenotypically syncytium inducing
(SI); exclusively uses CXCR4; and replicates well in CCR5 2/2 primary T cells. The recently discovered
coreceptors BOB and Bonzo are not used. Although early and persistent SI variants have been described in
longitudinal studies, this is the first demonstration of exclusive and persistent CXCR4 usage. With the caveat
that the earliest viruses available from this subject were from approximately 4 years following primary
infection, these data suggest that HIV-1 infection can be mediated and persistently maintained by viruses
which exclusively utilize CXCR4. The lack of evolution toward the available minor coreceptors in this subject
underscores the dominant biological roles of the major coreceptors CCR5 and CXCR4. This and two similar
subjects (R. Biti, R. Ffrench, J. Young, B. Bennetts, G. Stewart, and T. Liang, Nat. Med. 3:252–253, 1997; I.
Theodoreu, L. Meyer, M. Magierowska, C. Katlama, and C. Rouzioux, Lancet 349:1219–1220, 1997) showed
relatively rapid CD41 T-cell declines despite average or low initial viral RNA load. Since viruses which use
CXCR4 exclusively cannot infect macrophages, these data have implications for the relative infection of the
T-cell compartment versus the macrophage compartment in vivo and for the development of CCR5-based
therapeutics.
Cellular entry of human immunodeficiency virus type 1
(HIV-1) requires binding both to CD4 (14, 33, 40) and to one
of the seven transmembrane G-protein-coupled chemokine re-
ceptors recently discovered to act as coreceptors (2, 6, 8, 11, 16,
19, 20, 24, 46). Viruses able to infect cultured T-cell lines (T
tropic) are syncytium inducing (SI), are frequently found in
late-stage HIV disease, and utilize the chemokine receptor
CXCR4; macrophage-tropic (M-tropic) viruses are non-SI
(NSI) in T-cell lines, are found throughout disease, and utilize
CCR5 (2, 6, 8, 11, 16, 19, 20, 24, 46). Two other chemokine
receptors, CCR2B and CCR3, function as minor HIV-1 entry
coreceptors (11, 19, 48), with CCR3 likely playing a role in
central nervous system HIV-1 infection (27). Recently, two
seven-transmembrane receptors with extensive sequence ho-
mology to CCR5 and CXCR4—Bonzo (3, 17) and BOB (17,
22)—have been shown to mediate entry of simian immunode-
ficiency virus (SIV), as well as some M-tropic HIV-1 and
HIV-2 strains. Another seven-transmembrane receptor,
GPR1, mediates the entry of SIV but not HIV-1 (22). The CC
chemokines RANTES, MIP-1a, and MIP-1b are natural li-
gands for CCR5 (49, 51), and the CXC chemokine stromal-
cell-derived factor 1 (SDF-1) is the only known natural ligand
for CXCR4 (8, 46, 49, 51). Ligand binding to both receptors is
associated with G-protein-coupled signal transduction and leu-
kocyte chemoattraction (8, 46, 49, 51), as well as partial viral-
entry antagonism (2, 8, 11–13, 16, 20, 29, 46, 58). Viral entry
and signal transduction are separable in vitro functions for
CCR5 (4, 23, 26), but the two may be biologically related to
viral pathogenesis in vivo.
Most viral isolates recovered during primary and early
chronic infection are NSI regardless of the route of infection
(56, 59). Evolution of coreceptor use from CCR5 to CXCR4 is
coincident with viral phenotypic switch from NSI to SI and
progression to AIDS in approximately half of all HIV-1-sero-
positive subjects (31, 32, 34, 43, 54). A 32-bp inactivating de-
letion in CCR5 (CCR5 D32) common to northern European
populations (41) has been associated with delayed disease pro-
gression in heterozygotes (15, 18, 21, 28, 43, 50, 60) and espe-
cially in those harboring NSI virus (18, 43). Subjects homozy-
gous for CCR5 D32 (CCR5 2/2) are at a sharply reduced risk
for virus transmission (15, 21, 28, 38, 43, 52, 60). However,
reports of HIV-1 infected CCR5 2/2 individuals, by our group
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and others, demonstrate that this risk reduction is finite (5, 7,
47, 55). We now report the viral phenotype, replication kinet-
ics, macrophage tropism, and coreceptor usage of viruses de-
rived early and late in disease from an HIV-1-infected CCR5
2/2 subject.
MATERIALS AND METHODS
Case history and specimen availability. Details of the clinical history have
been reported previously (47). Briefly, patient UNC116 was born in 1969 with
severe hemophilia A and received over 500,000 U of non-heat-treated factor
VIII concentrates between 1978 and 1984. He had no other HIV-1 transmission
risk factors. UNC116 was enrolled in the Multicenter Hemophilia Cohort Study
(MHCS) with estimated HIV-1 infection in January 1982 and serologic diagnosis
in 1985. His time to a CD41 T-cell count of less than 200 cells/ml (4.4 years) and
progression to AIDS (13.7 years) were at the 7th and 42nd percentiles, respec-
tively, for the MHCS. The serum HIV-1 RNA concentration of 3.7 log10 cop-
ies/ml in 1986 was median for the MHCS. We previously showed that multiple
peripheral blood mononuclear cell (PBMC) DNA samples from UNC116 were
CCR5 2/2 (47). The subject’s parents were CCR5 2/2 and CCR5 1/2 with
confirmation of lineage by microsatellite DNA typing. Serum and plasma sam-
ples were available throughout this subject’s course, but PBMC samples were
available only at later time points.
HIV-1 molecular clones and isolates. The following infectious molecular
clones and viral isolates were obtained through the AIDS Research and Refer-
ence Program, Division of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health: pYU-2 from Beatrice Hahn and George
Shaw; pNL4-3 from Malcolm Martin; HIV-1ADA-M from Howard Gendelman;
HIV-1BaL from Suzanne Gartner, Mikulas Popovic and Robert Gallo; HIV-
1SF162 from Jay Levy; and HIV-189.6 from Ronald Collman. HIV-1 and HIV-2
infectious molecular clones LAI and ROD, respectively, were obtained from
Keith Peden. A molecular clone of JR-CSF was a gift of Irvin S. Y. Chen, and
subtype E primary isolates CM235 and CM240 were collected by the Walter
Reed Army Institute of Research. pNL4-3 is an infectious molecular clone of an
SI, T-tropic virus (1). pYU-2 is an NSI, M-tropic infectious molecular clone (37)
which uses the coreceptors CCR5 and CCR3 (11, 37). Both clones belong to
genetic subtype B. HIV-1ADA-M, HIV-1BaL, HIV-1JR-CSF, HIV-1CM235, HIV-
1CM240, and HIV-1SF162 are NSI viruses which exclusively use CCR5 (17; also,
data not shown), while HIV-189.6 is an SI, dual-tropic strain which uses CCR5,
CXCR4, CCR3, and CCR2B (19). Plasmids were propagated in Escherichia coli
DH5a and purified for transfection and PCR experiments by using Qiagen
columns (Qiagen, Inc., Chatsworth, Calif.).
Amplification and DNA sequencing of env V1 through V3 cDNA. Separate
100-ml aliquots of serum drawn from the subject in December 1985 and June
1986 were mixed with 900 ml of RNAzol (Tel-Test, Inc., Friendswood, Tex.) prior
to the addition of 10 mg of an E. coli rRNA carrier (Boehringer Mannheim,
Indianapolis, Ind.) and RNA purification as recommended by the manufacturer.
cDNA fragments representing HIV-1 env domains V1 through V3 were subse-
quently amplified, cloned, and sequenced as described previously (42). Control
amplifications in the absence of template were uniformly negative.
Viral RNA was isolated from a second 100-ml aliquot of serum drawn in June
1986 by using a Qiagen viral RNA isolation kit. The RNA was eluted with 50 ml
of H2O. Reverse transcriptase PCR (RT-PCR) was performed with primers
V3L2 (59-ACTCAACTGCTGTTAAATGG-39) and V3R1 (59-CACTTCTCCA
ATTGTCCCTCA-39) to produce an approximately 650-bp product spanning V3
to V5. The reaction conditions were as follows. Ten-microliter RT reaction
mixtures consisted of 5 ml of viral RNA, 13 PCR buffer (50 mM KCl, 10 mM Tris
[pH 8.3]), 5 mM MgCl2, 1 mM each deoxynucleoside triphosphate (United States
Biochemicals, Inc.), 7.5 pmol of primer V3R1, 10 U of RNase inhibitor (Perkin-
Elmer), and 25 U of Moloney murine leukemia virus (MLV) RT (Perkin-Elmer).
Reverse transcription was done at 42°C for 30 min, followed by 10 min at 99°C
to inactivate the RT. Forty microliters of a PCR master mix (13 PCR buffer, 2.5
mM MgCl2, 7.5 pmol of primer V3L2, 1.25 U of Perkin-Elmer AmpliTaq poly-
merase) was then added to the RT reaction mixture. PCR was carried out in a
Stratagene Gradient-40 Robocycler with a program of 96°C for 3 min, followed
by 40 cycles of 96°C for 45 s, 52°C for 45 s, and 72°C for 1 min. The RT-PCR
product was cloned into the pT7Blue vector (Novagen) and propagated in
DH5a. Clones were screened by amplifying the 141-bp V3 fragment by colony
PCR (36) with primers V3L4 and V3R5 and analyzing the colony PCR products
by the V3 heteroduplex tracking assay (V3-HTA) as described elsewhere (45).
The clones were sequenced with an ABI PRISM dye terminator kit (Perkin-
Elmer). cDNA amplicons representing regions V1 through V3 and V3 through
V5 were obtained in two separate laboratories. These sequences were both
unique to the laboratories where they were generated and highly related to each
other, mitigating the possibility of contamination.
V3-HTA. RT-PCR of the V3 region was performed as described elsewhere
(45) to generate a 141-bp product. The reaction conditions for this RT-PCR were
the same as above, except that primers V3L4 and V3R5 were used. Cycling
conditions were as described above with an annealing temperature of 51°C and
an extension time of 45 s. The PCR product described above was analyzed by
V3-HTA (45) to determine whether the plasma sample contained SI-like variants
and whether it was homogeneous. Heteroduplexes were formed between the
RT-PCR product and a 35S-labeled probe which contains a V3 sequence nearly
identical to the subtype B consensus from the JR-FL molecular clone (35). The
heteroduplexes were separated on a 12% polyacrylamide gel as described else-
where (45).
Construction of isogenic recombinant provirus. HXB2 proviral clones chi-
meric in the V3 region of env were generated from a cloned serum cDNA
sequence as previously described (39) except that the V3 fragments were gen-
erated by PCR and not by overlapping oligonucleotide synthesis (Fig. 1a). HIV
clones chimeric in domains V3 through V5 were generated as follows. A recom-
binant env subclone (pKMJ) was constructed for convenient replacement of a
560-bp BglII-BglII fragment spanning V3 to V5 in JR-FL. The pKMJ vector was
constructed by subcloning the 3.1-kb EcoRI-XhoI fragment of the pNL4-3 pro-
viral clone (1) into pET21a (Novagen), in which the BglII site had been destroyed
by Klenow fill-in. The 2.9-kb SacI-XhoI fragment was then replaced with the
same region from the pUC112-1 subclone of JR-FL. This subclone has only two
BglII sites which flank V3 to V5, which allows direct exchange of V3 to V5
sequences. Two of the 650-bp clones (1-7 and 5-3) generated from the June 1986
sample were chosen for insertion into a recombinant infectious clone. The V3 to
V5 sequences were reamplified from clones 1-7 and 5-3 with primers 59BGL
(59-ATTAGATCTGAAAATTTCACGGAC-39) and 39BGL (59-TCCTCCTCC
AGGTCTGAAGATCTC-39). Reaction mixtures contained 13 PCR buffer, 2.5
mM MgCl2, 200 mM each deoxynucleoside triphosphate, 5 pmol of each primer,
1 ng of plasmid, and 2.5 U of Gibco BRL Taq polymerase, in a final volume of
50 ml. Cycling conditions were as described above. The products were ligated into
the pT7Blue vector, and clones with inserts were sequenced by using the ABI
PRISM dye terminator kit. The BglII insert from one clone of each sequence (1-7
and 5-3) was ligated into the pKMJ vector to replace the JR-FL V3 to V5
sequence. Control recombinant clones were constructed by inserting the BglII-
BglII fragments from the pYU-2 and pNL4-3 molecular clones into pKMJ. The
EcoRI-XhoI fragment from each subclone was then ligated into pNL4-3 to make
infectious proviral clones (Fig. 1b). Recombinant molecular-clone DNA was
prepared from E. coli STBL2 (Gibco BRL) by using a Qiagen Plasmid Maxi kit.
The inserts of all isogenic recombinant proviral constructions were confirmed by
DNA sequence analysis.
Preparation of viral stocks from molecular clones. Twenty-microgram
amounts of proviral clones were transfected into 1.5 3 107 COS-1 cells by
electroporation (0.22 kV, 960 mF) and subsequently maintained in a humidified,
5% CO2 environment at 37°C for 48 h in Dulbecco modified Eagle medium
FIG. 1. Construction of isogenic recombinant proviruses. (a) Exogenous V3
region env sequences were inserted into a portion of the HIV-1HXB2 env gene
contained within the SalI-BamHI fragment and then inserted into the HIV-
1HXB2 proviral background. (b) Exogenous sequences V3 through V5 contained
by BglII sites were inserted into the HIV-1JR-FL background bounded by SacI
and XhoI sites and then inserted into the HIV-1NL4-3 proviral background.
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(DMEM) supplemented with 10% fetal calf serum (FCS) (PAA Laboratories,
Inc., Newport Beach, Calif.), 100 U of penicillin per ml, 100 mg of streptomycin
per ml, and 2 mM L-glutamine. Supernatants were saved, and 3 ml of fresh
medium was added to each well for an additional 24 h. Supernatant fluids were
then cleared by centrifugation at 300 3 g, filtered through 0.22-mm syringe filters
(Millipore, Bedford, Mass.), and monitored for p24 antigen production by HIV-1
core antigen enzyme-linked immunosorbent assay (Coulter, Hialeah, Fla.). Ap-
proximately 2 3 106 phytohemagglutinin (PHA)-stimulated seronegative donor
PBMC were exposed to 1 ml of the p24 antigen-positive COS-1 cell supernatant.
After overnight infection, cells were washed and maintained in culture medium
(RPMI 1640 supplemented with 15% FCS, 100 U of penicillin per ml, 100 mg of
streptomycin per ml, and 2 mM L-glutamine) containing 20 U of human recom-
binant interleukin 2 (IL-2). Virus replication was monitored by p24 antigen
production, and culture supernatant harvested at peak p24 antigen production
was used to measure the 50% tissue culture infective dose (TCID50). Stocks for
HIV-1 isolates LAI and JR-CSF, HIV-2 isolate ROD, and MLV-pseudotyped
HIV-1 were prepared as described elsewhere (17).
Twenty-microgram samples of proviral DNA of the June 1986 chimeric clones
(1-7 and 5-3) and the YU-2 and NL4-3 control chimeric clones were used in
calcium phosphate transfection of HeLa cells as previously described (10). Su-
pernatants were harvested, and virus production was quantitated by RT assay (9).
Virus stocks were produced by infection of uninfected PHA-stimulated PBMC.
Recovery of plasma virus. Frozen plasma from June 1994 was thawed at 37°C,
and 100 ml was added to triplicate wells of a 96-well microtiter plate. An aliquot
of 5 3 104 PHA-stimulated PBMC was added to each well and incubated
overnight. Cells were washed and maintained in IL-2-supplemented culture
medium. One-half of the culture supernatant was harvested and replaced every
2 to 3 days for 20 days. Culture supernatant from one p24 antigen-positive well
was used to prepare an expanded virus stock.
PBMC replication kinetics. In triplicate wells of a 96-well microtiter plate,
1.5 3 105 PHA-stimulated PBMC per well were infected overnight with ;100
TCID50 of each virus stock. Cells were washed and maintained in IL-2-supple-
mented culture medium. One-half of the culture supernatant was harvested and
replaced every other day for 20 days. Culture supernatant from triplicate wells
was pooled, and p24 antigen was measured in batch at the end of the time course.
Macrophage replication kinetics. Macrophages were prepared from PBMC of
HIV-1-seronegative donors by overnight adherence to plastic flasks precoated
with heat-inactivated normal human serum. Nonadherent cells were removed by
vigorous washing with culture medium, and macrophages were detached with
cold Ca21- and Mg21-free phosphate-buffered saline (PBS) as described else-
where (25). Macrophages were then seeded at 105 cells per well in flat-bottom
96-well microtiter plates and maintained in culture medium supplemented with
10% normal human serum for 7 days prior to infection. To evaluate virus growth
kinetics, cells in triplicate wells were exposed overnight to ;400 TCID50 of virus
stock and washed thoroughly, and culture supernatant p24 antigen was moni-
tored every 3 to 4 days for 30 days. M-tropic (ADA-M, SF162, and 89.6) and
T-tropic (MN) viruses were propagated in PHA-stimulated PBMC for use as
positive and negative macrophage infectivity controls, respectively.
MT-2 phenotyping assay. The ability of the PBMC-derived viruses to induce
syncytia in MT-2 cells was evaluated by using the AIDS Clinical Trials Group
consensus protocol (30). MT-2 cells were exposed to 200 TCID50 of each virus in
duplicate wells. Viruses were judged to be of the SI phenotype if three or more
syncytia per low-magnification (1003) field were observed during a 21-day ob-
servation period.
Coreceptor usage in GHOST cells. Virus coreceptor preferences were assayed
by single-round infection using a novel indicator cell panel (32a). Human osteo-
sarcoma (HOS) cells were stably transduced with human CD4 encoded on the
MLV vector pMV7neo. HOS.T4 cells were next stably cotransfected with
pCMV-hph and a reporter construct encoding humanized green fluorescent
protein (GFP) under the control of the HIV-2 long terminal repeat (LTR).
GFP-HOS.T4 (GHOST) clones were screened for their ability to induce GFP
after transduction with the HIV-1 tat gene encoded on an MLV vector. One
clone which demonstrated a high level of Tat-dependent activated transcription
of GFP was chosen and subsequently stably transduced with the MLV vector
pBABE-puro (44), encoding various chemokine receptor or HIV/SIV coreceptor
genes. GHOST cells were maintained in DMEM supplemented with 10% FCS,
500 mg of G418 per ml, and 100 mg of hygromycin per ml. GHOST cells
expressing coreceptor genes were additionally supplemented with 1 mg of puro-
mycin per ml. In addition to the parental line which served as a background
control, 10 other GHOST cell lines expressing human CCR1, CCR2B, CCR3,
CCR4, CCR5, CXCR4, GPR1, BOB/GPR15, or Bonzo/STRL33 were used in
analyses.
To determine virus coreceptor usage, 2 3 104 cells were plated per well of
12-well dishes the night prior to infection. The next day, equivalent amounts of
virus stocks were applied in the presence of 10 mg of Polybrene per ml onto cells
for 2 h, after which virus-containing medium was replaced with growth medium.
Two days postinfection, cells were detached from plates with PBS–0.02% EDTA,
fixed in 2% paraformaldehyde–PBS for 1 h, washed twice with PBS, and resus-
pended in PBS–2% FCS–0.2% sodium azide. Cells were then analyzed for
humanized-GFP expression on a Becton Dickinson FACScan using CellQuest
software. For each infection, the percentage of FL1-positive cells in mock-
infected GHOST cells was subtracted from that of virally infected GHOST cells.
The percentage of FL1-positive virally infected parental cells was then subtracted
from that of all other GHOST cell infections to control for low-level, endogenous
CXCR4 expression. Finally, these corrected percentages of FL1-positive cells
were normalized for relative cell line GFP production reflected by parallel
infections with amphotropic-MLV envelope (MLV-E)-pseudotyped HIV-1
(which enters GHOST cells independently of CD4 or coreceptor utilization) by
multiplying them by the ratio of the mean GHOST MLV-E percent FL1 posi-
tives to coreceptor-specific MLV-E percent FL1 positives.
Coreceptor usage in HOS.CD4.coreceptor cells (p24 assay). Virus coreceptor
entry was evaluated by using HOS cells transduced with CD4 alone or in com-
bination with CCR1, CCR2B, CCR3, CCR4, CCR5, or CXCR4 (generously
provided by N. Landau, Aaron Diamond AIDS Research Center). HOS cells
(maintained in DMEM supplemented with 10% FCS, 100 U of penicillin per ml,
100 mg of streptomycin per ml, 2 mM L-glutamine, and 1 mg of puromycin per ml)
were seeded at 5 3 103 per well in flat-bottom 96-well microtiter plates. In
triplicate wells, HOS cells were exposed overnight to 500 to 1,000 TCID50 of
virus, and gently washed, and p24 antigen in the culture supernatant was mea-
sured on days 4 and 7. p24 production in HOS.CD4 wells was subtracted from
that in HOS.CD4.coreceptor wells to account for low-level CXCR4 expression in
these cells.
Nucleotide sequence accession numbers. Nucleotide sequences V1 to V3 and
V3 to V5 derived from patient UNC116 have been assigned GenBank accession
no. AF034375 to AF034385.
RESULTS
HIV-1 V3 sequences from patient UNC116 are homogenous
and are SI by both genotype and phenotype. We previously
showed that HIV-1 env sequences amplified from clinical sam-
ples obtained from patient UNC116 between 1985 and 1992
were of the SI genotype based on the presence of positively
charged amino acids in the deduced amino acid sequence of
the V3 loop region (47) and contained minimal sequence di-
versity (47; also, data not shown). The presence of the SI
genotype and homogeneity were confirmed at the viral cDNA
population level by the newly described V3-HTA (45) (Fig. 2).
V3 sequences were amplified by RT-PCR from viral RNA
isolated from a June 1986 serum sample from subject UNC116.
Heteroduplexes were formed between these RT-PCR products
and a radioactively labeled probe containing the near consen-
FIG. 2. Analysis by V3-HTA. V3 loop RT-PCR products from the June 1986
serum sample from patient UNC116 (lane 86) and control YU-2 and NL4-3
recombinant proviral clones were annealed with the JR-FL V3 probe that was
35S labeled on one strand. The heteroduplexes were resolved on a native poly-
acrylamide gel and visualized by autoradiography. Only the bottom half of the
autoradiograph is shown. The positions of the single-stranded probe (upper
arrow) and double-stranded probe homoduplexes (lower arrow) are indicated.
Heteroduplexes in each lane resolved between the single-stranded probe and
probe homoduplexes.
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sus V3 sequence for subtype B viruses. After resolution of the
heteroduplexes, a single dominant band was seen on the au-
toradiograph, indicating limited V3 quasispecies diversity in
the 1986 serum sample. The intermediate mobility of the het-
eroduplexes from UNC116, compared with the faster NSI con-
trol YU-2 and the slower SI control NL4-3 (whose envelope
sequences are derived from HIV-1LAI [1]), indicated that the
sequences had clustering of mutations that has been associated
with the SI genotype (45). Nucleotide sequencing of molecular
clones containing env cDNA sequences V1 to V3 and V3 to V5
from the December 1985 and June 1986 samples revealed a
range of interclone divergence of 2.1 to 5.7%, which rose to
only 7.5 to 9.9% by inclusion of cDNA sequences derived from
a June 1994 plasma sample; all clones were of the SI genotype
and were highly associated phylogenetically (data not shown;
the sequences have been deposited in GenBank).
The earliest available specimens for UNC116 consisted of
small volumes of serum that had been stored under nonideal
conditions for successful viral culture. Rather than attempt
viral culture of this serum, we constructed isogenic recombi-
nant proviruses containing exogenous sequences of either V3
or V3 through V5 (Fig. 1) derived from UNC116 env cDNAs
as described in Materials and Methods. The predominant V3
sequence in the December 1985 serum sample was put into the
HXB2 proviral clone to create the 12/85 chimera (Fig. 1a). The
complete HXB2 proviral clone was used as a control for this
recombinant. The 6/86 chimeras were made by putting two
different V3 to V5 sequences (1-7 and 5-3) derived from the
June 1986 serum sample into a JR-FL env gene within an
NL4-3 proviral clone (Fig. 1b). Each of these V3 to V5 se-
quences had the same V3 sequence as that used in the 12/85
recombinant virus. Control recombinant viruses were con-
structed by placing the V3 to V5 sequences from the YU-2
(NSI control) and NL4-3 (SI control) proviral clones into the
same NL4-3/JR-FL recombinant provirus. A viral isolate from
late in disease was obtained from a June 1994 plasma specimen
with high viral load.
The three early (12/85 and 6/86) viral chimeras, the late
(6/94) plasma viral isolate, and the control viruses were tested
for biological phenotype in the MT-2 cell assay. All of the
viruses except the YU-2 recombinant control virus were phe-
notypically SI (Table 1 and data not shown).
The viral quasispecies displays exclusive and persistent
CXCR4 coreceptor utilization. Equivalent amounts of the viral
stocks were used to infect GHOST cells to determine relative
coreceptor utilization in a single-step infection assay. This
HOS cell line is stably transduced with human CD4, GFP
under the control of the Tat-sensitive HIV-2 promoter, and
specific human coreceptor cDNAs. Infection of these GHOST
cells by HIV-1 results in the production of GFP that can be
detected by flow cytometry less than 48 h postinfection.
Whereas mock infection of these cells results in virtually no
signal above background (red in Fig. 3), infection with CD4/
coreceptor-independent amphotropic-MLV-E-pseudotyped
HIV-1 virions results in 5 to 32% of these cells becoming
positive for GFP production (green in Fig. 3). Inspection of the
fluorescence-activated cell sorter profiles in Fig. 3 and the
relative coreceptor utilization in Table 1 for the 12/85 viral
chimera and 6/94 plasma isolate show CXCR4 use to the ex-
clusion of the other known entry coreceptors (CCR2B, CCR3,
CCR5, BOB, and Bonzo). CCR1, CCR4, and GPR1 were also
tested and were not used by these stocks (data not shown). The
SI control virus HIV-1LAI exclusively used CXCR4, whereas
the NSI control virus HIV-1JR-CSF exclusively used CCR5.
HIV-2ROD used primarily CXCR4 but also CCR3, BOB, and
Bonzo; SIVmac1A11 used CCR5 and BOB; and SIVagmTYO
used CCR5, BOB, and Bonzo. Exclusive CXCR4 usage was
confirmed for the 12/85 and 6/86 viral chimeras and 6/94
plasma isolate in a HOS.CD4.coreceptor assay using p24 an-
tigen readout, in which CXCR4, CCR1, CCR2B, CCR3,
CCR4, and CCR5 were tested (data not shown). Lower viral
titers for the 6/86 viral chimeras compared with the 12/85
chimeras or 6/94 plasma isolate obviated coreceptor typing
with GHOST cells, whose readout is 2 days. HOS.CD4.core-
ceptor typing with p24 antigen readout at 7 days afforded
greater sensitivity for viruses with delayed replication kinetics.
The viral quasispecies replicates in CCR5 1/1 and CCR5
2/2 PBMC but not in macrophages. The early viral chimeras
and late plasma isolate from UNC116 displayed typical repli-
cation kinetics in CCR5 1/1 PBMC compared with virus de-
rived from the M-tropic molecular clone pYU-2, virus derived
from the T-tropic molecular clone pNL4-3, the dual-tropic
isolate 89.6, and the NSI isolates ADA-M and BaL (Fig. 4a).
The 12/85 chimera and the 89.6 and NL4-3 viruses also repli-
cated well in seronegative CCR5 2/2 PBMC, while YU-2,
ADA-M, and BaL did not (Fig. 4b). The replication of the 6/86
V3-V5 viral chimeras was delayed in these cells. This observa-
tion could reflect stochastic selection of relatively less fit mem-
bers of the quasispecies or the reduced activity of a chimeric
protein or involve subtle host cell differences between the
CCR5 1/1 and 2/2 PBMC.
To rule out the use of as yet undiscovered coreceptors on
primary macrophages, the replication kinetics of the UNC116
and control viruses were studied in CCR5 1/1 primary mac-
rophages (Fig. 4c). All of the UNC116 viruses and the SI
control HIV-1MN failed to replicate in macrophages, but the
NSI primary isolates CM235, CM240, SF162, and ADA-M, as
well as the dual-tropic 89.6, replicated to various degrees in
primary macrophages. Thus, if the UNC116 viruses are capa-
ble of using as yet undiscovered HIV-1 entry coreceptors, these
putative receptors are not expressed in primary macrophages
under culture conditions.
DISCUSSION
Given the importance of CCR5 coreceptor utilization in
transmission and early HIV-1 disease, the virology of HIV-1-
infected CCR5 2/2 individuals provides an important insight
into HIV-1 pathogenesis. We now report that the viral quasi-
species from one such individual is persistently homogenous,
SI, and T tropic and exclusively uses the HIV-1 entry corecep-
tor CXCR4 during the observation period. Although early and
TABLE 1. Biological phenotype and coreceptor usage of
experimental and control viral stocks
Virus (phenotypea)
% GHOST cell infectionb
CXCR4 CCR2B CCR3 CCR5 BOB Bonzo
12/85 V3 chimerac (SI) 100.0 0 0 0 0 0
6/94 plasma isolate (SI) 100.0 0 0 0 0 0
HIV-1LAI (SI) 100.0 0 0 0 0 0
HIV-2ROD (SI) 85.5 0 2.7 0 6.8 5.0
HIV-1JRCSF (NSI) 0 0 0 100 0 0
SIVmac1A11 0 0 0 71.2 28.8 0
SIVagmTYO 0 0 0 75.7 6.1 18.2
a Determined by the ACTG consensus MT-2 cell assay.
b Normalized to MLV-E-pseudotyped HIV-1 infection as described in Mate-
rials and Methods.
c The 6/86 V3-V5 chimera stock was not tested in the GHOST cell assay. This
SI stock was tested in HOS.CD4.coreceptor cells with p24 readout and found to
exclusively use CXCR4 (data not shown).
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persistent SI variants (32, 34) or evolution to exclusive CXCR4
usage (53) has been previously found in longitudinal cohorts,
UNC116 represents the first demonstration of exclusive and
persistent CXCR4 usage in an HIV-1-infected individual, al-
beit with the important caveat that the earliest viral sampling in
this study occurred approximately 4 years postinfection.
As most other primary viruses reported to date can use
CCR5 for cell entry, we speculate that patient UNC116 was
FIG. 3. HIV-1 entry coreceptor typing of viral stocks in GHOST cells. HOS cells nonpermissive for HIV-1 infections were transduced with human CD4 and the
GFP under the control of the HIV-2 LTR to generate parental GHOST cells. These cells were then individually transduced with the HIV-1 entry coreceptor cDNAs
indicated at the top. HIV-1 entry and subsequent tat gene expression transactivates the HIV-2 LTR and upregulates the expression of GFP. Following infection of
parental and coreceptor-transduced cells with equivalent amounts of specific viral stocks (indicated at the left), the cells were fixed and analyzed by flow cytometry. For
each fluorescence-activated cell sorter profile, linear forward side scatter is plotted against log fluorescence intensity for GFP in the FL1 window. Basal-level production
of GFP is red; transactivated GFP expression is green.
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initially exposed to a swarm containing viruses capable of using
both CCR5 and CXCR4 but only viruses with CXCR4 entry
capacity were propagated in the context of the host environ-
ment. The quasispecies did not expand to use “minor” core-
ceptors such as CCR2B, CCR3, BOB, Bonzo, or GPR1, a
finding consistent with the dominant roles of CCR5 and
CXCR4 as HIV-1 entry coreceptors. As virus from UNC116
was first sampled roughly 4 years postinfection, it is not clear
when selection for exclusive CXCR4 use occurred, but our
data suggest that virus with CXCR4-restricted coreceptor uti-
lization was present during most, if not all, of the period of
chronic HIV infection. As these observations are based on a
single patient, it will be critical to learn if they apply to other
CCR5 2/2 seropositive individuals. Within this context, it may
be notable that virus from a laboratory worker initially infected
with the CXCR4-exclusive, T-tropic strain HIV-1IIIB was sub-
sequently recovered in both autologous macrophage culture
and donor PBMC. The PBMC-derived virus was capable of
passage into the human T-cell line H9 (57), indicative of the
utilization of both CCR5 and CXCR4. Together, these reports
suggest that HIV-1 quasispecies may evolve to fit the CCR5
environment of the host.
UNC116 V3 sequences embedded in the env background of
the exclusive CXCR4-using virus HIV-1HXB2 and sequences
V3 to V5 embedded in the env background of the exclusive
CCR5-using virus HIV-1JR-FL resulted in viral chimeras re-
stricted to CXCR4. Although we cannot formally exclude the
possibility that sequences outside the V3 region contributed to
coreceptor selectivity, this finding confirms previous data
showing the strong influence of the V3 domain upon CCR5
and CXCR4 usage (13).
SI variant, CXCR4-using HIV-1 quasispecies are associated
with increased in vivo virulence in cohort studies in which the
presence of CCR5 2/2 infected individuals is either absent or
undocumented but is presumably very rare (31, 32, 34, 43, 54).
The increased pathogenicity of such strains appears to be in-
dependent of the viral load (31). In agreement with those
observations, UNC116 and two similar patients with estimable
dates of infection (7, 55) showed relatively rapid CD41 T-cell
decline despite average to low early viral RNA load. Because
case reports of HIV-1-infected patients with the CCR5 2/2
genotype are few and potentially biased toward those with a
better clinical course, available data are insufficient to predict
the prognosis of such persons. However, these reports provide
no evidence that, once infected with HIV-1, CCR5 2/2 pa-
tients have a better prognosis than other persons.
We speculate that HIV-1 infection in CCR5 2/2 individuals
involves the persistent and dominant (if not exclusive) use of
the coreceptor CXCR4 with cell-free infection largely confined
to the T-cell (not macrophage) compartment. Infection of
macrophages in such individuals may occur through cell-cell
fusion events, although this could limit the ability of macro-
phages to serve as a reservoir of viral replication. Limited data
suggest that HIV-1 quasispecies may evolve in response to the
host’s CCR5 environment and that HIV-1-infected CCR5 2/2
patients have no better prognosis than other infected persons.
These points should be carefully considered in the design of
therapeutic modalities such as blockade of CCR5 by small
molecules or bone marrow transplantation with CCR5 2/2
stem cells.
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